Improving survival and reducing treatment damage in Hodgkin lymphoma.

Impact: Health and wellbeing

Narrative

Our research has led to fundamental treatment changes in Hodgkin lymphoma (HL):
• Individualising treatment, leading to fewer treatment-related second cancers and less heart disease for early stage HL patients, and less lung damage in advanced HL.
• Changing clinical guidelines on radiotherapy treatment, reducing dose and field size, decreasing patient risk.
• Introduction of Brentuximab Vedotin in Europe and US for advanced HL, the first new treatment option and change to clinical practice in over 40 years.
• Creation of national Breast Screening after Radiotherapy (BARD) dataset, which identifies women at risk of radiotherapy-induced breast cancer following HL treatment, and its introduction into Public Health England policy.
Impact date1 Aug 2013 → 31 Dec 2020
Category of impactHealth and wellbeing
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Cancer
  • Manchester Cancer Research Centre

Documents & Links

Related content